YU70199A - Primena stimulatora lučenja hormona rasta za izradu farmaceutskih preparata za lečenje otpornosti na insulin - Google Patents
Primena stimulatora lučenja hormona rasta za izradu farmaceutskih preparata za lečenje otpornosti na insulinInfo
- Publication number
- YU70199A YU70199A YU70199A YU70199A YU70199A YU 70199 A YU70199 A YU 70199A YU 70199 A YU70199 A YU 70199A YU 70199 A YU70199 A YU 70199A YU 70199 A YU70199 A YU 70199A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- useful
- formula
- growth hormone
- compounds
- increasing
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003324 growth hormone secretagogue Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5079097P | 1997-06-25 | 1997-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU70199A true YU70199A (sh) | 2003-01-31 |
Family
ID=21967444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU70199A YU70199A (sh) | 1997-06-25 | 1998-06-05 | Primena stimulatora lučenja hormona rasta za izradu farmaceutskih preparata za lečenje otpornosti na insulin |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US6448263B1 (h) |
| EP (1) | EP1000085B1 (h) |
| JP (2) | JP2000514099A (h) |
| KR (1) | KR20010014224A (h) |
| CN (2) | CN1152049C (h) |
| AP (1) | AP1145A (h) |
| AR (1) | AR012256A1 (h) |
| AT (1) | ATE305477T1 (h) |
| AU (1) | AU747510B2 (h) |
| BG (1) | BG104008A (h) |
| BR (1) | BR9810477A (h) |
| CA (1) | CA2294464A1 (h) |
| CO (1) | CO4950621A1 (h) |
| DE (1) | DE69831745T2 (h) |
| DZ (1) | DZ2539A1 (h) |
| EA (1) | EA002089B1 (h) |
| EG (1) | EG21712A (h) |
| ES (1) | ES2248899T3 (h) |
| HN (1) | HN1998000088A (h) |
| HR (1) | HRP980361A2 (h) |
| HU (1) | HUP0001922A3 (h) |
| ID (1) | ID24345A (h) |
| IL (7) | IL133626A0 (h) |
| IN (1) | IN189724B (h) |
| IS (1) | IS5275A (h) |
| MA (1) | MA24581A1 (h) |
| NO (1) | NO996205L (h) |
| NZ (1) | NZ500655A (h) |
| OA (1) | OA11242A (h) |
| PA (1) | PA8452601A1 (h) |
| PE (1) | PE105399A1 (h) |
| PL (1) | PL337659A1 (h) |
| SK (1) | SK175699A3 (h) |
| TN (1) | TNSN98113A1 (h) |
| TR (1) | TR199903257T2 (h) |
| TW (1) | TW553943B (h) |
| UA (1) | UA64751C2 (h) |
| WO (1) | WO1998058949A1 (h) |
| YU (1) | YU70199A (h) |
| ZA (1) | ZA985546B (h) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| US6541634B2 (en) * | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
| EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
| DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US20060128615A1 (en) * | 2002-09-18 | 2006-06-15 | Pierrette Gaudreau | Ghrh analogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| US7828934B2 (en) * | 2004-12-21 | 2010-11-09 | Hercules Incorporated | Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems |
| US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| RU2403902C1 (ru) * | 2009-06-15 | 2010-11-20 | Илья Николаевич Медведев | Способ снижения биологического возраста при нарушении толерантности к глюкозе |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| MA20150428A1 (fr) | 2012-05-03 | 2015-11-30 | Novartis Ag | Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline |
| BR112015029586B1 (pt) * | 2013-05-28 | 2022-05-03 | Raqualia Pharma Inc | Formas polimorfas |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2016021191A1 (en) * | 2014-08-05 | 2016-02-11 | Raqualia Pharma Inc. | Serine derivatives as ghrelin receptor agonists |
| TW201625613A (zh) * | 2014-10-31 | 2016-07-16 | 拉夸里亞創藥股份有限公司 | 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物 |
| US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| WO2024217441A1 (zh) * | 2023-04-21 | 2024-10-24 | 长春金赛药业有限责任公司 | GHSR 1a激动剂、药物组合物及其制备方法和应用 |
| CN119285632A (zh) * | 2024-10-09 | 2025-01-10 | 威海中腾医药科技有限公司 | 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
| US3202660A (en) | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
| AU676525B2 (en) | 1992-11-06 | 1997-03-13 | Merck & Co., Inc. | Substituted dipeptide analogs promote release of growth hormone |
| SK282166B6 (sk) | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
| SK56296A3 (en) | 1993-11-09 | 1997-02-05 | Merck & Co Inc | Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them |
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
| EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| ES2323159T3 (es) | 1995-12-22 | 2009-07-07 | Novo Nordisk A/S | Compuestos con propiedades de liberacion de la hormona del crecimiento. |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| ES2283055T3 (es) * | 1997-06-25 | 2007-10-16 | Pfizer Inc. | Derivados dipeptidos como secretagogos de la hormona de crecimiento. |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/uk unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Application Discontinuation
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko not_active Ceased
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU70199A (sh) | Primena stimulatora lučenja hormona rasta za izradu farmaceutskih preparata za lečenje otpornosti na insulin | |
| IL122958A0 (en) | Method of identifying a calcimimetic compound | |
| UY25059A1 (es) | Sal tartrato de un dipeptido sustituido, útil como secretagogo de la hormona del crecimiento. | |
| ATE369848T1 (de) | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie | |
| SI2017276T1 (sl) | Fenil-karboksamidne spojine, uporabne za tretiranje bolečine | |
| BRPI0408784A (pt) | método para usar um composto | |
| BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
| AU2330202A (en) | Treatment of statin side effects | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| DE69916273D1 (de) | Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| WO2002096362A3 (en) | Method for treating fibrotic diseases or other indications vi | |
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| MXPA04004826A (es) | Antagonista del receptor de quimioquinas y metodos para su uso. | |
| GB2426517A (en) | Methods and agents for inhibiting dynamin-dependent endocytosis | |
| ATE153500T1 (de) | Verfahren zur inhibierung der fibrose | |
| NO921595L (no) | Superaktive grf analoger | |
| ECSP982556A (es) | Tratamiento de la resistencia a la insulina | |
| TW360629B (en) | Calcium receptor active molecules | |
| TW200503673A (en) | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same |